WAT

In November 2025, Waters reported better-than-expected performance and raised its earnings guidance. In February 2026, Waters completed its acquisition of Biosciences and Diagnostic Solutions from Becton, Dickinson and Company, but the stock declined due to investor caution. In April 2026, Waters launched its omniDAWN Multi-Angle Light Scattering Photometer and received FDA clearance for its Onclarity HPV Self-Collection Kit, leading to a stock price rebound. In May 2026, Waters reported strong first-quarter 2026 financial results and raised its full-year revenue growth guidance, causing the stock to surge.